Adding a second diabetes drug to your current treatment
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a thiazolidinedione (TZD), or a combination of both to your current DPP4 inhibitor-based treatment can improve blood sugar control in type 2 diabetes. It aims to find the best add-on option for people who need extra help managing their diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 75 years old.
- You have type 2 diabetes and your HbA1c (average blood sugar over 3 months) is between 7.5% and 11.0%.
- You have been taking a DPP4 inhibitor (like sitagliptin, saxagliptin, linagliptin, or alogliptin) alone or with metformin and/or a sulfonylurea (like glipizide or glyburide) for at least 8 weeks without changing the dose.
- You have not used a TZD (like pioglitazone or rosiglitazone) or an SGLT2 inhibitor (like empagliflozin, dapagliflozin, or canagliflozin) in the past 8 weeks.
- You are not currently taking four or more diabetes medications.
- You do not have serious heart, kidney, liver, or bladder problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
This study compares two medications, trelagliptin and sitagliptin, to see which works better for people with type 2 diabetes. It might be an option if you are already taking metformin but your blood sugar levels are still not under control.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This study tests a new medication called LID104 added to your usual metformin to see if it improves blood sugar control in people with type 2 diabetes. If you qualify, you'll get the study drug or a placebo (inactive pill) to compare how well it works.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
Hear when a new Hyperglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.